5 Key Takeaways

• 1

  The FDA has approved Tregzi, the first regulatory T cell-based immunotherapy for blood cancer patients undergoing stem cell transplantation.

• 2

  Tregzi aims to improve chronic graft-versus-host disease-free survival in adults receiving allogeneic stem cell transplants.

• 3

  The approval of Tregzi is supported by the PRECISION-T trial, which showed significant survival benefits compared to standard transplants.

• 4

  Epicrispr's EPI-321 therapy may increase lean muscle volume in patients with facioscapulohumeral muscular dystrophy, according to early trial results.

• 5

  New CAR T-cell therapies are being developed to target specific mutations in rare blood cancers and glioblastoma, showing promising preclinical results.